SMARCA4 and neoplasm: Similar to SCCOHT, our analysis in multiple NSCLC datasets of diverse tumor staging including the most comprehensive Director’s Challenge data set suggests that reduced SMARCA4 expression is associated with chemoresistance in NSCLC.